Tech Company Financing Transactions

Tempest Therapeutics Funding Round

On 3/29/2018, Tempest Therapeutics raised $70 million in Series B funding from F-Prime Capital, Quan Capital and Versant Ventures.

Transaction Overview

Company Name
Tempest Therapeutics
Announced On
3/29/2018
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series B
Investors

F-Prime Capital (Lead Investor) (Robert Weisskoff)

Quan Capital (Lead Investor) (Stella Xu)

Versant Ventures (Lead Investor) (Brad Bolzon)

Eight Roads

Foresite Capital

Lilly Asia Ventures

Proceeds Purpose
Proceeds from the Series B financing will support the advancement of lead program TPST-8844 into the clinic in the next 12 months as well as advancement of at least two other programs into the clinic shortly thereafter.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Sansome St. 3690
San Francisco, CA 94104
USA
Phone
Undisclosed
Website
www.tempesttx.com
Email Address
[email protected]
Overview
Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways.
Profile
Tempest Therapeutics LinkedIn Company Profile
Social Media
Tempest Therapeutics Company Twitter Account
Company News
Tempest Therapeutics News
Facebook
Tempest Therapeutics on Facebook
YouTube
Tempest Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Thomas Dubensky
  Thomas Dubensky LinkedIn Profile  Thomas Dubensky Twitter Account  Thomas Dubensky News  Thomas Dubensky on Facebook
Chief Medical Officer
Ginna Laport
  Ginna Laport LinkedIn Profile  Ginna Laport Twitter Account  Ginna Laport News  Ginna Laport on Facebook
Chief Scientific Officer
Peppi Prasit
  Peppi Prasit LinkedIn Profile  Peppi Prasit Twitter Account  Peppi Prasit News  Peppi Prasit on Facebook
VP - Bus. Development
Alicia Levey
  Alicia Levey LinkedIn Profile  Alicia Levey Twitter Account  Alicia Levey News  Alicia Levey on Facebook
VP - Operations
Elia Borbas
  Elia Borbas LinkedIn Profile  Elia Borbas Twitter Account  Elia Borbas News  Elia Borbas on Facebook
VP - Operations
Jennifer McDevitt
  Jennifer McDevitt LinkedIn Profile  Jennifer McDevitt Twitter Account  Jennifer McDevitt News  Jennifer McDevitt on Facebook
VP - R & D
Amanda Enstrom
  Amanda Enstrom LinkedIn Profile  Amanda Enstrom Twitter Account  Amanda Enstrom News  Amanda Enstrom on Facebook
VP - R & D
Chan Whiting
  Chan Whiting LinkedIn Profile  Chan Whiting Twitter Account  Chan Whiting News  Chan Whiting on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/29/2018: Canvas Medical venture capital transaction
Next: 3/29/2018: Singlera Genomics venture capital transaction

 

Share this article

 

About Database of VC Transactions

Our team works diligently to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.